EDITORIAL
Hepatitis C Virus (HCV) infection poses a huge burden worldwide, as well as on the Bangladeshis, being a leading cause of all forms of chronic liver diseases next only to HBV 1,2 . A recent study in Bangladesh showed a prevalence of 0.88%, though figures vary due to lack of representative population study in Bangladesh 2 . The advent of new generation oral antiviral therapy has led to major improvements in efficacy and tolerability but has also resulted in an explosion of data with increased treatment choice complexity. The questions of who should be treated and with what regimen, will be increasingly complex to address and will require careful consideration. As therapy improves, identification and care of patients who need treatment will be the next challenge 3 . We need to update ourselves continuously to provide optimum treatment to our patients.
HCV is a positive-strand RNA virus encoding a polyprotein that undergoes proteolytic cleavage to 10 polypeptides, each with distinct functions. The structural proteins consist of two envelope glycoproteins, both of which are targets of host antibody response, and the core protein, which interacts with progeny viral genomes for assembly of the virus. The nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B form a complex with viral RNA to initiate viral replication in a cytoplasmic membranous structure. The new direct-acting antiviral agents (DAAs) target these non-structural proteins to prevent viral replication 4 
